Target family: Lysophospholipid (LPA) receptors (type: gpcr)
Target: LPA<sub>2</sub> receptor

Ligand: 2-oleoyl-LPA (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity: 8 pEC50
Reference (Journal): Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.
Published in: FEBS Lett

Ligand: AM966 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 4.6 pIC50
Reference (Journal): A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
Published in: Br J Pharmacol

Ligand: AM966 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.8 pIC50
Reference (Journal): A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
Published in: Br J Pharmacol

Ligand: BrP-LPA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.329999923706055 pIC50
Reference (Journal): Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Published in: Cancer Res

Ligand: BrP-LPA (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.610000133514404 pKi
Reference (Journal): Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.
Published in: Cancer Res

Ligand: compound 15 [PMID: 18178086] (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents.
Published in: Bioorg Med Chem Lett

Ligand: CpX (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.900000095367432 pEC50
Reference (Journal): Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.
Published in: J Pharmacol Exp Ther

Ligand: CpX (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.099999904632568 pKi
Reference (Journal): Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.
Published in: J Pharmacol Exp Ther

Ligand: CpY (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.5 pEC50
Reference (Journal): Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.
Published in: J Pharmacol Exp Ther

Ligand: decyl dihydrogen phosphate (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.4 pEC50
Reference (Journal): Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors.
Published in: Mol Pharmacol

Ligand: dodecylphosphate (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.2 pEC50
Reference (Journal): Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors.
Published in: Mol Pharmacol

Ligand: dodecyl-thiophosphate (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6 pEC50
Reference (Journal): Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
Published in: J Med Chem

Ligand: farnesyl diphosphate (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 5.679999828338623 pIC50
Reference (Journal): Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
Published in: J Biol Chem

Ligand: farnesyl monophosphate (Metabolite)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation.
Published in: J Biol Chem

Ligand: GRI977143 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 4.480000019073486 pEC50
Reference (Journal): Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.
Published in: Mol Pharmacol

Ligand: H2L5186303 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Identification of non-lipid LPA3 antagonists by virtual screening.
Published in: Bioorg Med Chem

Ligand: H2L5186303 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.050000190734863 pIC50
Reference (Journal): Structure-based drug design identifies novel LPA3 antagonists.
Published in: Bioorg Med Chem

Ligand: Ki16425 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.25 pKi
Reference (Journal): Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Published in: Mol Pharmacol

Ligand: LPA (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate.
Published in: Mol Pharmacol

Ligand: LPA (Metabolite)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.
Published in: Bioorg Med Chem Lett

Ligand: LPA (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid.
Published in: J Biol Chem

Ligand: LPA (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.
Published in: Curr Med Chem

Ligand: NAEPA (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pEC50
Reference (Journal): LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.
Published in: Curr Med Chem

Ligand: oleoyl-thiophosphate (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 6.610000133514404 pEC50
Reference (Journal): Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin.
Published in: J Med Chem

Ligand: Radioprotectin-1 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 11.300000190734863 pEC50
Reference (Journal): The LPA<sub>2</sub> receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids.
Published in: Cell Signal

Ligand: Radioprotectin-1 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 7.599999904632568 pEC50
Reference (Journal): The LPA<sub>2</sub> receptor agonist Radioprotectin-1 spares Lgr5-positive intestinal stem cells from radiation injury in murine enteroids.
Published in: Cell Signal

Ligand: UCM-14216 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pKd
Reference (Journal): Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice.
Published in: J Med Chem

Ligand: UCM-14216 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 5.71999979019165 pIC50
Reference (Journal): Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA<sub>2</sub>), UCM-14216, Ameliorates Spinal Cord Injury in Mice.
Published in: J Med Chem